Leucrose
Based on 1 Customer Validation
Leucrose (5-O-α-D-Glucopyranosyl-D-fructose) is an orally active Sucrose (HY-B1779) isomer naturally found in pollen and honey. Leucrose promotes phosphorylation of JAK1 and STAT6, reduces pro-inflammatory mediators and cytokinesas (TNFα, and IL-1β), increases M2 macrophage polarization and suppresses DSS (HY-116282C)-induced colitis. Leucrose suppresses hepatic triglyceride accumulation, improves fasting blood glucose levels, and regulates hepatic lipogenesis and fatty acid β-oxidation in high-fat diet-induced obese mice. Leucrose is slowly hydrolyzed into glucose and fructose by α-glucosidase and acts as as a sugar substitute in diet.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 98.53%
- CAS No.: 7158-70-5
- 화학식: C12H22O11
- 분자량:342.30
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
Biological Activity
|
JAK1 |
STAT6 |
IL-1β |
Leucrose (24 h) does not alter RAW 264.7 macrophage cell viability relative to glucose treatment in DMEM containing IL4 (20 ng/mL) and total glucose
content (25 mM) partially substituted with leucrose, but upregulates M2 macrophage markers (CD163, Arg1) and increases JAK1/STAT6 phosphorylation[1].
Leucrose is hydrolyzed into
glucose and fructose by α-glucosidase in the small intestine and suppresses adipogenesis and down-regulates adipogenesis-related gene expression in 3T3-L1 adipocytes[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RAW 264.7 macrophage cells
-
Concentration:25% substitution of 25 mM glucose content; 50% substitution of 25 mM glucose content
-
Incubation Time:24 h
-
Result:Significantly exceeds levels in the non-treated control group across all treated groups.
Shows no significant difference between leucrose-treated groups (25% and 50% substitution) and the glucose-treated group.
-
Cell Line:RAW 264.7 macrophage cells
-
Concentration:25% substitution of 25 mM glucose content; 50% substitution of 25 mM glucose content
-
Incubation Time:24 h (with 20 ng/mL IL-4)
-
Result:Increases CD163 levels by 99.0% in the 50% leucrose substitution group compared to the high-glucose control group.
Increases Arg1 levels by 78.6% in the 50% leucrose substitution group compared to the high-glucose control group.
Significantly increases p-JAK1 levels in both the 25% and 50% leucrose substitution groups compared to the high-glucose control group.
Significantly increases p-STAT6 levels in both the 25% and 50% leucrose substitution groups compared to the high-glucose control group.
Leucrose (25-50% of total sucrose replaced; p.o.; ad libitum in diet; 12 weeks) improves fasting blood glucose levels, reduces hepatic triglyceride accumulation, downregulates hepatic lipogenesis-related genes, and upregulates hepatic β-oxidation-related genes in obese mice, with the 50% replacement showing greater potency for hepatic triglyceride reduction and β-oxidation gene activation[2].
Leucrose (25% indiet; p.o.; daily; 6 weeks) supports normal growth in weanling male SPF-Sprague-Dawley rats, with body weight gain, protein efficiency, and energy efficiency statistically equivalent to sucrose or corn starch controls[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male, 5-week-old, 18-20 g, DSS-induced colitis model)[1]
-
Dosage:25% of total sucrose content replaced with leucrose; 50% of total sucrose content replaced with leucrose
-
Administration:p.o.; ad libitum in diet; continuously for 5 weeks
-
Result:Attenuated DAI scores at day 19 by 59.2% (25% replacement) and 56.9% (50% replacement) compared to the DSS-only group.
Suppressed DAI area under the curve (AUC) scores by 25.4% (25% replacement) and 37.3% (50% replacement) compared to the DSS-only group.
Restored colon length by 12.6% (25% replacement) and 20.3% (50% replacement) compared to the DSS-only group.
Reduced myeloperoxidase (MPO) activity by 30.4% (25% replacement) and 31.9% (50% replacement) compared to the DSS-only group.
Reduced colon tissue iNOS protein levels by 89.3% (50% replacement) and COX2 protein levels by 84.0% (50% replacement) compared to the DSS-only group.
Down-regulated colon tissue mRNA levels of MCP-1, TNFα, and IL-1β by 44.7%, 34.7%, and 81.1% respectively in the 50% replacement group compared to the DSS-only group.
Reduced plasma IL-1β concentrations by 36.9% (25% replacement) and 34.4% (50% replacement) compared to the DSS-only group.
Significantly reduced colon tissue F4/80-positive macrophage infiltration compared to the DSS-only group in both leucrose groups.
Significantly increased colon tissue mRNA levels of M2 polarization markers Arg1 and Ym1 in both leucrose groups, and CD206 in the 50% replacement group only, compared to the DSS-only group.
-
Animal Model:C57BL/6 (5-week-old male, 18-20 g, high-fat diet-induced obesity model)[2]
-
Dosage:25% of total sucrose replaced with leucrose; 50% of total sucrose replaced with leucrose
-
Administration:p.o.; ad libitum in diet; 12 weeks
-
Result:Reduced fasting blood glucose levels to 141 mg/dL (L25 group) and 133 mg/dL (L50 group), compared to HFD control's 184 mg/dL.
Reduced hepatic triglyceride content to 70 mg/g in L50 group compared to HFD control; L25 group showed non-significant reduction.
Downregulated peroxisome proliferator-activated receptor γ (Pparg) in L25 and L50 groups; downregulated sterol regulatory element binding protein 1C (Srebf1) in both leucrose groups; fatty acid synthase (Fasn) showed non-significant downward trend.
Upregulated peroxisome proliferator-activated receptor α (Ppara) and acyl CoA oxidase (Acox1) in L50 group; upregulated carnitine palmitoyltransferase 1A (Cpt1a) in both L25 and L50 groups, reversing HFD-induced downregulation.
Chemical Information
-
CAS No. 7158-70-5
-
Appearance Solid
-
분자량 342.30
-
화학식 C12H22O11
-
Color White to off-white
-
SMILES
OCC([C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]([C@H]([C@@H]([C@H]1O)O)O)CO)=O
-
Synonyms
5-O-α-D-Glucopyranosyl-D-fructose
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
용액&용해도
H2O : 70 mg/mL (204.50 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
순도&문서
-
Data Sheet (281 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 2.9214 mL | 14.6071 mL | 29.2141 mL | 73.0354 mL |
| 5 mM | 0.5843 mL | 2.9214 mL | 5.8428 mL | 14.6071 mL | |
| 10 mM | 0.2921 mL | 1.4607 mL | 2.9214 mL | 7.3035 mL | |
| 15 mM | 0.1948 mL | 0.9738 mL | 1.9476 mL | 4.8690 mL | |
| 20 mM | 0.1461 mL | 0.7304 mL | 1.4607 mL | 3.6518 mL | |
| 25 mM | 0.1169 mL | 0.5843 mL | 1.1686 mL | 2.9214 mL | |
| 30 mM | 0.0974 mL | 0.4869 mL | 0.9738 mL | 2.4345 mL | |
| 40 mM | 0.0730 mL | 0.3652 mL | 0.7304 mL | 1.8259 mL | |
| 50 mM | 0.0584 mL | 0.2921 mL | 0.5843 mL | 1.4607 mL | |
| 60 mM | 0.0487 mL | 0.2435 mL | 0.4869 mL | 1.2173 mL | |
| 80 mM | 0.0365 mL | 0.1826 mL | 0.3652 mL | 0.9129 mL | |
| 100 mM | 0.0292 mL | 0.1461 mL | 0.2921 mL | 0.7304 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Leucrose Related Classifications
HY-123115 Related Classifications
Powered by Bioz
- Leucrose
- 7158-70-5
- 5-O-α-D-Glucopyranosyl-D-fructose
- JAK
- STAT
- TNF Receptor
- Interleukin Related
- JAK1/STAT6 signaling pathway
- SPF-Sprague-Dawley rats
- RAW 264.7 macrophages
- STAT6
- dextran sulfate sodium-induced colitis
- C57BL/6 mice
- non-alcoholic fatty liver disease
- JAK1
- M2 macrophage polarization
- 3T3-L1 adipocytes
- Inhibitor
- inhibitor
- inhibit